Detail
Článek
Článek online
FT
Medvik - BMČ
  • Je něco špatně v tomto záznamu ?

Anti-Cancer Potential of a new Derivative of Caffeic Acid Phenethyl Ester targeting the Centrosome

C. Giordano, J. Kendler, M. Sexl, S. Kollman, M. Varenicja, B. Szabó, G. Timelthaler, D. Kirchhofer, O. Hollóczki, SD. Turner, R. Moriggl, L. Kenner, M. Touaibia, O. Merkel

. 2025 ; 81 (-) : 103582. [pub] 20250305

Jazyk angličtina Země Nizozemsko

Typ dokumentu časopisecké články

Perzistentní odkaz   https://www.medvik.cz/link/bmc25009317

Anaplastic Large Cell Lymphoma (ALCL) is an aggressive T-cell lymphoma affecting children and young adults. About 30% of patients develop therapy resistance therefore new precision medicine drugs are highly warranted. Multiple rounds of structure-activity optimization of Caffeic Acid Phenethyl Ester have resulted in CM14. CM14 causes upregulation of genes involved in oxidative stress response and downregulation of DNA replication genes leading to G2/M arrest and subsequent apoptosis induction. In accordance with this, an unbiased proteomics approach, confocal microscopy and molecular modeling showed that TUBGCP2, member of the centrosomal γ-TuRC complex, is a direct interaction partner of CM14. CM14 overcomes ALK inhibitor resistance in ALCL and is also active in T-cell Acute Lymphoblastic Leukemia and Acute Myeloid Leukemia. Interestingly, CM14 also induced cell death in docetaxel-resistant prostate cancer cells thus suggesting an unexpected role in solid cancers. Thus, we synthesized and thoroughly characterized a novel TUBGCP2 targeting drug that is active in ALCL but has also potential for other malignancies.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc25009317
003      
CZ-PrNML
005      
20250429135456.0
007      
ta
008      
250415e20250305ne f 000 0|eng||
009      
AR
024    7_
$a 10.1016/j.redox.2025.103582 $2 doi
035    __
$a (PubMed)40073758
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a ne
100    1_
$a Giordano, Catello $u Department of Pathology, Medical University of Vienna, Vienna, Austria
245    10
$a Anti-Cancer Potential of a new Derivative of Caffeic Acid Phenethyl Ester targeting the Centrosome / $c C. Giordano, J. Kendler, M. Sexl, S. Kollman, M. Varenicja, B. Szabó, G. Timelthaler, D. Kirchhofer, O. Hollóczki, SD. Turner, R. Moriggl, L. Kenner, M. Touaibia, O. Merkel
520    9_
$a Anaplastic Large Cell Lymphoma (ALCL) is an aggressive T-cell lymphoma affecting children and young adults. About 30% of patients develop therapy resistance therefore new precision medicine drugs are highly warranted. Multiple rounds of structure-activity optimization of Caffeic Acid Phenethyl Ester have resulted in CM14. CM14 causes upregulation of genes involved in oxidative stress response and downregulation of DNA replication genes leading to G2/M arrest and subsequent apoptosis induction. In accordance with this, an unbiased proteomics approach, confocal microscopy and molecular modeling showed that TUBGCP2, member of the centrosomal γ-TuRC complex, is a direct interaction partner of CM14. CM14 overcomes ALK inhibitor resistance in ALCL and is also active in T-cell Acute Lymphoblastic Leukemia and Acute Myeloid Leukemia. Interestingly, CM14 also induced cell death in docetaxel-resistant prostate cancer cells thus suggesting an unexpected role in solid cancers. Thus, we synthesized and thoroughly characterized a novel TUBGCP2 targeting drug that is active in ALCL but has also potential for other malignancies.
650    _2
$a lidé $7 D006801
650    12
$a kyseliny kávové $x farmakologie $x chemie $7 D002109
650    12
$a fenethylalkohol $x analogy a deriváty $x farmakologie $x chemie $7 D010626
650    12
$a centrozom $x účinky léků $x metabolismus $7 D018385
650    12
$a protinádorové látky $x farmakologie $x chemie $7 D000970
650    12
$a apoptóza $x účinky léků $7 D017209
650    _2
$a nádorové buněčné linie $7 D045744
650    _2
$a proliferace buněk $x účinky léků $7 D049109
655    _2
$a časopisecké články $7 D016428
700    1_
$a Kendler, Jonatan $u Department of Biological Sciences and Pathobiology, Pharmacology and Toxicology, University of Veterinary Medicine Vienna, Vienna, Austria
700    1_
$a Sexl, Maximilian $u Department of Biological Sciences and Pathobiology, Pharmacology and Toxicology, University of Veterinary Medicine Vienna, Vienna, Austria
700    1_
$a Kollman, Sebastian $u Department of Biological Sciences and Pathobiology, Pharmacology and Toxicology, University of Veterinary Medicine Vienna, Vienna, Austria
700    1_
$a Varenicja, Maxim $u Department of Physical Chemistry, University of Debrecen, Debrecen, Hungary
700    1_
$a Szabó, Boglárka $u Department of Physical Chemistry, University of Debrecen, Debrecen, Hungary
700    1_
$a Timelthaler, Gerald $u Center for Cancer Research, Medical University of Vienna, Vienna, Austria
700    1_
$a Kirchhofer, Dominik $u Center for Cancer Research, Medical University of Vienna, Vienna, Austria
700    1_
$a Hollóczki, Oldamur $u Department of Physical Chemistry, University of Debrecen, Debrecen, Hungary
700    1_
$a Turner, Suzanne D $u European Research Initiative on ALK-Related Malignancies (ERIA), Cambridge, UK; Division of Cellular and Molecular Pathology, Department of Pathology, University of Cambridge, Addenbrooke's Hospital, Cambridge, UK; Faculty of Medicine, Masaryk University, Brno, Czech Republic
700    1_
$a Moriggl, Richard $u Department of Biosciences and Medical Biology, Paris Lodron University of Salzburg, Salzburg, Austria
700    1_
$a Kenner, Lukas $u Department of Pathology, Medical University of Vienna, Vienna, Austria; European Research Initiative on ALK-Related Malignancies (ERIA), Cambridge, UK; Christian Doppler Laboratory (CDL) for Applied Metabolomics, Medical University of Vienna, Vienna, Austria; Unit of Laboratory Animal Pathology, University of Veterinary Medicine, Vienna, Austria; Center for Biomarker Research in Medicine (CBMed) Core Lab 2, Medical University of Vienna, Vienna, Austria; Department of Molecular Biology, Umeå University, Umeå, Sweden
700    1_
$a Touaibia, Mohamed $u Chemistry and Biochemistry Department, Université de Moncton, Moncton, New Brunswick, Canada. Electronic address: mohamed.touaibia@umoncton.ca
700    1_
$a Merkel, Olaf $u Department of Pathology, Medical University of Vienna, Vienna, Austria; European Research Initiative on ALK-Related Malignancies (ERIA), Cambridge, UK. Electronic address: olaf.merkel@meduniwien.ac.at
773    0_
$w MED00196805 $t Redox biology $x 2213-2317 $g Roč. 81 (20250305), s. 103582
856    41
$u https://pubmed.ncbi.nlm.nih.gov/40073758 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y - $z 0
990    __
$a 20250415 $b ABA008
991    __
$a 20250429135452 $b ABA008
999    __
$a ok $b bmc $g 2310971 $s 1246398
BAS    __
$a 3
BAS    __
$a PreBMC-MEDLINE
BMC    __
$a 2025 $b 81 $c - $d 103582 $e 20250305 $i 2213-2317 $m Redox biology $n Redox Biol $x MED00196805
LZP    __
$a Pubmed-20250415

Najít záznam

Citační ukazatele

Možnosti archivace